tert-butyl 5-aminooctahydro-2H-isoindole-2-carboxylate | 1252572-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: tert-butyl 5-aminooctahydro-2H-isoindole-2-carboxylate
• 英文别名: tert-butyl 5-amino-1,3,3a,4,5,6,7,7a-octahydroisoindole-2-carboxylate
• CAS: 1252572-44-3
• 化学式: C₁₃H₂₄N₂O₂
• 分子量: 240.346
• InChiKey: LLTJKZQPTQJCDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2,6-bis(benzyloxy)pyridin-3-yl)-7-bromo-1-methyl-1H-indazole 、 tert-butyl 5-aminooctahydro-2H-isoindole-2-carboxylate 在 [1,3-bis(2,6-diisoheptylphenyl)-4,5-dichloroimidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以0.7 g的产率得到tert-butyl 5-((3-(2,6-bis(benzyloxy)pyridin-3-yl)-1-methyl-1H-indazol-7-yl)amino)octahydro-2H-isoindole-2-carboxylate
  参考文献：
  名称：

  [EN] TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS
  [FR] AGENTS DE DÉGRADATION BIFONCTIONNELS DE QUINOLONE-BCL6 TRICYCLIQUES

  摘要：

  This disclosure provides compounds of Formula (I) (e.g., Formula (I-aa) (e.g., Formula (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5), or (I-aa-6)), Formula (I-a) (e.g., Formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5), or (I-a-6)), Formula (I-bb) (e.g., Formula (I-bb-1) or (I-bb-2)), or Formula (I-b) (e.g., Formula (I-b-1) or (I-b-2))) or Formula (II), or a pharmaceutically acceptable salt thereof, that induce degradation of a BCL6 protein. These compounds are useful, for example, for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein as well as methods of using and making the same.

  公开号：

  WO2023240038A1
• 作为产物：
  描述：

  2-Boc-5-氧-八氢-异吲哚 在 ammonium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 以62 %的产率得到tert-butyl 5-aminooctahydro-2H-isoindole-2-carboxylate
  参考文献：
  名称：

  WO2023/64345

  摘要：

  公开号：

文献信息

• SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：Xi Ning

  公开号：US20150274704A1

  公开（公告）日：2015-10-01

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新型杂环芳基化合物、药物可接受的盐及其制剂，可用于预防、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含这些化合物的药物可接受的组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• Substituted heteroaryl compounds and methods of use
  申请人：Calitor Sciences, LLC

  公开号：US09403801B2

  公开（公告）日：2016-08-02

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物、药学上可接受的盐及其制剂，用于预防、治疗或减轻蛋白激酶介导的疾病的严重程度。本发明还提供了包含这些化合物的药学上可接受的组合物和使用这些组合物治疗蛋白激酶介导的疾病的方法。
• US9403801B2
  申请人：——

  公开号：US9403801B2

  公开（公告）日：2016-08-02
• [EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：CALITOR SCIENCES LLC

  公开号：WO2015148867A1

  公开（公告）日：2015-10-01

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.